Literature DB >> 1918136

Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.

P H Quax1, G N van Muijen, E J Weening-Verhoeff, L R Lund, K Danø, D J Ruiter, J H Verheijen.   

Abstract

Five out of six human melanoma cell lines tested were able to degrade in vitro a smooth muscle cell extracellular matrix in a plasmin-dependent way. In three of these five cell lines, this process was mediated by tissue-type plasminogen activator (t-PA) and in the other two cell lines by urokinase-type plasminogen activator (u-PA). All melanoma cell lines produced t-PA mRNA and protein, whereas only the two cell lines showing u-PA-mediated matrix degradation produced u-PA mRNA and protein. These latter cell lines also produced plasminogen activator inhibitor type-1 (PAI-1) and type-2 (PAI-2) mRNA and protein. u-PA receptor (u-PA-R) mRNA and binding of radiolabeled u-PA was found in all melanoma cell lines. The metastatic capacity of these cell lines was studied in nude mice. All cell lines were able to develop primary tumors at the subcutaneous inoculation site. The production of plasminogen activators, their inhibitors and urokinase receptor by subcutaneous tumors corresponded with the production by the parental cell lines in vitro. The two u-PA and PAI-1 producing cell lines showed the highest frequency to form spontaneous lung metastases after subcutaneous inoculation, whereas five of the six cell lines formed lung colonies after intravenous inoculation. In conclusion, u-PA mediated matrix degradation in vitro and production of u-PA and PAI-1 by human melanoma cell lines correlated with their ability to form spontaneous lung metastasis in nude mice. No correlation was found with the ability to form lung colonies after intravenous injection. These findings suggest a role for u-PA and PAI-1 in a relatively early stage of melanoma metastasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918136      PMCID: PMC2289921          DOI: 10.1083/jcb.115.1.191

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  61 in total

1.  Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.

Authors:  P H Quax; R T van Leeuwen; H W Verspaget; J H Verheijen
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

2.  Metalloproteinases and cancer invasion and metastasis.

Authors:  G Murphy; J J Reynolds; R M Hembry
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

3.  Characterization of the cellular binding site for the urokinase-type plasminogen activator.

Authors:  A Estreicher; A Wohlwend; D Belin; W D Schleuning; J D Vassalli
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

4.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

Authors:  N Behrendt; E Rønne; M Ploug; T Petri; D Løber; L S Nielsen; W D Schleuning; F Blasi; E Appella; K Danø
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

5.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.

Authors:  V Ellis; T C Wun; N Behrendt; E Rønne; K Danø
Journal:  J Biol Chem       Date:  1990-06-15       Impact factor: 5.157

6.  Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.

Authors:  M V Cubellis; P Andreasen; P Ragno; M Mayer; K Danø; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

8.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

9.  Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.

Authors:  J F Cajot; W D Schleuning; R L Medcalf; J Bamat; J Testuz; L Liebermann; B Sordat
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

10.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.

Authors:  L Ossowski
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  29 in total

1.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.

Authors:  G de Jong; L Bartels; M Kedde; E M E Verdegaal; M A Gillissen; S E Levie; M G Cercel; S E van Hal-van Veen; C Fatmawati; D van de Berg; E Yasuda; Y B Claassen; A Q Bakker; S H van der Burg; R Schotte; J Villaudy; H Spits; M D Hazenberg; P M van Helden; K Wagner
Journal:  Cancer Immunol Immunother       Date:  2020-11-23       Impact factor: 6.968

3.  Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.

Authors:  M R Gyetko; G H Chen; R A McDonald; R Goodman; G B Huffnagle; C C Wilkinson; J A Fuller; G B Toews
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.

Authors:  T D Brooks; J Slomp; P H Quax; A C De Bart; M T Spencer; J H Verheijen; P A Charlton
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines.

Authors:  L H Brail; R P Hill
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

6.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

7.  Role of fibroblasts in the regulation of proinflammatory interleukin IL-1, IL-6 and IL-8 levels induced by keratinocyte-derived IL-1.

Authors:  I L Boxman; C Ruwhof; O C Boerman; C W Löwik; M Ponec
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

8.  Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved.

Authors:  Ine Lentacker; Bart Geers; Joseph Demeester; Stefaan C De Smedt; Niek N Sanders
Journal:  Mol Ther       Date:  2009-07-21       Impact factor: 11.454

9.  The biology of haematogenous metastasis in human uveal malignant melanoma.

Authors:  I W McLean
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 10.  Adhesion molecules and their role in cancer metastasis.

Authors:  R M Lafrenie; M R Buchanan; F W Orr
Journal:  Cell Biophys       Date:  1993 Aug-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.